CG oncology, Inc. (CGON)
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
Research Workspace
Put CGON beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRanks in the weakest quality tier of its industry — roughly the bottom 39%, softest on free-cash-flow margins.
View QualityMiddle-of-the-pack management execution.
View ManagementThis stock is volatile — it swings about 2% on a typical day and fell roughly 27% in its worst 12-month stretch.
View RiskCGON's growth depends on advancing the Phase 2 CORE-008 clinical trial results. Revenue performance has been weak, with the last quarter missing expectations. CGON trades at a valuation that lacks a clean multiple, making it hard to assess its price against peers. The market currently reflects growth expectations that align with forecasts. A specific risk is the 62% probability of missing outlooks, which could lead to further downward pressure. Peer multiples imply a price about 15% above where it trades. This read is provisional.
Trailing returns as of 2026-09-14. CGON is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering CGON (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare CGON with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CGON Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put CGON next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance Phase 2 CORE-008 clinical trial results
Cretostimogene readout is crucial for Phase 2 trial progress.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.

Phase 3 data indicates significant progress in bladder cancer treatment.
BLA progress is crucial for regulatory approval.
Leadership consolidation may enhance commercialization efforts.
Positive analyst rating supports valuation outlook.
Increased price target reflects positive data impact.